LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article: Percutaneous aspiration of aortic valve vegetation in a patient with aortic valve endocarditis.

    Cioci, Anthony Louis / Hutton, Anneka / Yi, Slee / Khoriaty, George / Gottlieb, Gary / Cartledge, Richard / Rubenstein, Mark

    Clinical case reports

    2024  Volume 12, Issue 4, Page(s) e8724

    Abstract: Key clinical message: Percutaneous aspiration for debulking of vegetations in right-sided infective endocarditis has been well-described, however, this technique can be employed successfully for left-sided vegetations in select high-risk patients.: ... ...

    Abstract Key clinical message: Percutaneous aspiration for debulking of vegetations in right-sided infective endocarditis has been well-described, however, this technique can be employed successfully for left-sided vegetations in select high-risk patients.
    Abstract: We report a case of percutaneous aspiration of an aortic valve vegetation in a patient with prosthetic valve endocarditis. This novel approach was selected after patient declined surgical intervention for an enlarging vegetation despite antibiotic therapy. The procedure was successful, resulting in the complete removal of solid vegetation without complications.
    Language English
    Publishing date 2024-03-29
    Publishing country England
    Document type Case Reports
    ZDB-ID 2740234-4
    ISSN 2050-0904
    ISSN 2050-0904
    DOI 10.1002/ccr3.8724
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: A multicenter study of nutraceutical drinks for cholesterol (evaluating effectiveness and tolerability).

    Karl, Mitchell / Rubenstein, Mark / Rudnick, Chad / Brejda, John

    Journal of clinical lipidology

    2012  Volume 6, Issue 2, Page(s) 150–158

    Abstract: Background: We hypothesized that a nutraceutical formulation containing small amounts of bioactive constituents that exert cholesterol-lowering effects by different mechanisms may exhibit synergistic efficacy with a clean tolerability profile. The ... ...

    Abstract Background: We hypothesized that a nutraceutical formulation containing small amounts of bioactive constituents that exert cholesterol-lowering effects by different mechanisms may exhibit synergistic efficacy with a clean tolerability profile. The purpose of this study was to evaluate nutraceutical fruit-flavored drinks with and without red yeast rice (RYR) for effects on low-density lipoprotein (LDL) and total cholesterol.
    Methods: In double-blinded fashion, 79 subjects were randomized to one of three fruit-flavored drinks, ie, a placebo, and two active drinks containing niacin, phytosterol esters, L-carnitine, vitamin C, and Co-Q-10, one with and without RYR, twice daily. Primary end points were LDL and total cholesterol percent reductions from baseline. Secondary end points were high-density lipoprotein and C-reactive protein percent change from baseline. Physician contact and laboratory work were obtained at baseline, 4 weeks, and 8 weeks of subject participation.
    Results: A total of 59 subjects completed the study. The placebo group and the group receiving the nutraceuticals without RYR showed no change in primary or secondary end points. The nutraceutical drink with RYR reduced total cholesterol at week 4 by 13% (-35 mg/dL) and week 8 by 14% (-46 mg/dL). LDL cholesterol decreased 17.1% at 4 weeks (-28 mg/dL) and 17.8% at week 8 (-30 mg/dL). In the effective drink arm containing nutraceuticals and RYR there were no biochemical or subjective intolerance, with the exception of one subject who experienced headache.
    Conclusions: A nutraceutical drink with RYR can be a safe and effective natural alternative to pharmacologic therapies for people intolerant to or refusing statins but still in need of achieving and maintaining a healthy and low cholesterol level.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Anticholesteremic Agents/adverse effects ; Anticholesteremic Agents/chemistry ; Anticholesteremic Agents/pharmacology ; Beverages ; Biological Products/adverse effects ; Biological Products/chemistry ; Biological Products/pharmacology ; Chemistry, Pharmaceutical ; Cholesterol/blood ; Demography ; Dietary Supplements/adverse effects ; Endpoint Determination ; Humans ; Lipoproteins, LDL/blood ; Male ; Middle Aged ; Surveys and Questionnaires ; Young Adult
    Chemical Substances Anticholesteremic Agents ; Biological Products ; Lipoproteins, LDL ; red yeast rice ; Cholesterol (97C5T2UQ7J)
    Language English
    Publishing date 2012-03
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 2365061-8
    ISSN 1876-4789 ; 1933-2874
    ISSN (online) 1876-4789
    ISSN 1933-2874
    DOI 10.1016/j.jacl.2011.09.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Spontaneous spiral dissection of a LIMA-LAD bypass graft: a case report.

    Wong, Philip / Rubenstein, Mark / Inglessis, Ignacio / Pomerantsev, Eugene / Ferrell, Margaret / Leinbach, Robert

    Journal of interventional cardiology

    2004  Volume 17, Issue 4, Page(s) 211–213

    Abstract: We describe an unusual case of spontaneous spiral dissection of a LIMA-LAD bypass graft presenting with an acute coronary syndrome. This complex lesion was treated percutaneously with multiple coronary stents. ...

    Abstract We describe an unusual case of spontaneous spiral dissection of a LIMA-LAD bypass graft presenting with an acute coronary syndrome. This complex lesion was treated percutaneously with multiple coronary stents.
    MeSH term(s) Acute Disease ; Aged ; Aneurysm, Dissecting/surgery ; Angioplasty, Balloon, Coronary ; Coronary Artery Bypass/adverse effects ; Humans ; Internal Mammary-Coronary Artery Anastomosis ; Male ; Stents
    Language English
    Publishing date 2004-08
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 1036325-7
    ISSN 1540-8183 ; 0896-4327
    ISSN (online) 1540-8183
    ISSN 0896-4327
    DOI 10.1111/j.1540-8183.2004.02085.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2719: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Short-term intravenous eptifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injury.

    Rubenstein, Mark H / Finn, Aloke V / Leinbach, Robert C / Hollenbach, Stanley / Aretz, H Thomas / Virmani, Renu / Gold, Herman K

    Journal of the American College of Cardiology

    2004  Volume 43, Issue 2, Page(s) 287–294

    Abstract: Objectives: This study was designed to determine in a dog model of coronary thrombosis whether short-term eptifibatide (Ep) combined with low-dose plasminogen activator (rt-PA) inhibits platelet recruitment at sites of endothelial damage after ... ...

    Abstract Objectives: This study was designed to determine in a dog model of coronary thrombosis whether short-term eptifibatide (Ep) combined with low-dose plasminogen activator (rt-PA) inhibits platelet recruitment at sites of endothelial damage after normalization of platelet function.
    Background: Ep plus reduced-dose rt-PA has not previously been shown to render a recanalized coronary artery resistant to platelet recruitment after normalization of platelet function.
    Method: Inhibition of platelet recruitment was studied by scanning electron microscopy (SEM) in a canine model of left anterior descending (LAD) thrombosis. In phase I treatment groups were: 1) Ep (n = 6); 2) Ep + rt-PA (n = 6); 3) rt-PA (n = 6); and 4) placebo (n = 4). Coronary blood flow was monitored and LAD segments excised for SEM after 90-min infusion of study drug. In phase II, dogs were randomized to Ep alone (n = 5) or to Ep + rt-PA (n = 5). Coronary blood flow was monitored during and 120 min after cessation of drug when platelet function had returned to normal and LAD segments were excised.
    Results: All animals except placebo showed reflow. In phase I, SEM showed an absence of platelet aggregates with Ep alone and with Ep + rt-PA, but not with rt-PA alone. In phase II, SEM showed an intimal surface devoid of mural thrombus and platelet aggregates only in Ep + rt-PA treated arteries. Ep-alone treated arteries showed new platelet aggregates at sites of residual mural thrombus.
    Conclusions: Short-term infusion Ep plus low-dose rt-PA acutely neutralizes the ability of damaged endothelial surfaces to recruit new platelets by inhibiting platelet aggregation and eliminating residual mural thrombus.
    MeSH term(s) Animals ; Coronary Artery Disease/drug therapy ; Coronary Circulation/drug effects ; Coronary Thrombosis/drug therapy ; Dogs ; Drug Therapy, Combination ; Endothelium, Vascular/drug effects ; Eptifibatide ; Infusions, Intravenous ; Models, Animal ; Peptides/administration & dosage ; Peptides/pharmacology ; Plasminogen Activators/pharmacology ; Platelet Activation/drug effects ; Platelet Aggregation Inhibitors/administration & dosage ; Platelet Aggregation Inhibitors/pharmacology ; Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors ; Tissue Plasminogen Activator/pharmacology
    Chemical Substances Peptides ; Platelet Aggregation Inhibitors ; Platelet Glycoprotein GPIIb-IIIa Complex ; Plasminogen Activators (EC 3.4.21.-) ; Tissue Plasminogen Activator (EC 3.4.21.68) ; Eptifibatide (NA8320J834)
    Language English
    Publishing date 2004-01-21
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 605507-2
    ISSN 1558-3597 ; 0735-1097
    ISSN (online) 1558-3597
    ISSN 0735-1097
    DOI 10.1016/j.jacc.2003.08.039
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1846: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 196: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Cardiopulmonary bypass induces release of soluble CD40 ligand.

    Nannizzi-Alaimo, Lisa / Rubenstein, Mark H / Alves, Veronica L / Leong, Gil Y / Phillips, David R / Gold, Herman K

    Circulation

    2002  Volume 105, Issue 24, Page(s) 2849–2854

    Abstract: Background: Cardiopulmonary bypass (CPB) is known to induce platelet activation, thrombosis, thrombocytopenia, and a systemic inflammatory response. It is known that CD40 ligand (CD40L) exists in platelets, that a soluble form of this protein (sCD40L) ... ...

    Abstract Background: Cardiopulmonary bypass (CPB) is known to induce platelet activation, thrombosis, thrombocytopenia, and a systemic inflammatory response. It is known that CD40 ligand (CD40L) exists in platelets, that a soluble form of this protein (sCD40L) is released on platelet activation, that platelets are the primary source of sCD40L in blood, and that sCD40L is involved in thrombosis and inflammation. The present study was designed to determine whether sCD40L is released during CPB. Methods and Results- Blood was obtained from patients undergoing CPB-requiring surgery and analyzed for sCD40L, interleukin-6, and platelet factor 4 and beta-thromboglobulin (markers of platelet activation). Platelets were also isolated and analyzed for their levels of CD40L. Plasma levels of sCD40L increased >1.7-fold (from 0.29 to 0.51 ng/mL, P=0.001) within 1 hour on CPB and increased further to 3.7-fold (to 1.08 ng/mL, P=0.03) 2 hours after the procedure. Half of the released sCD40L was cleared in 2 hours, which allowed the sCD40L to return to approximately baseline levels 8 hours after the procedure. The platelet content of CD40L was decreased by 40% (2.675 to 1.64 ng/10(8) platelets, P=0.001) 1 hour after initiation of CPB and was similar to that observed for platelet factor 4 and beta-thromboglobulin. Interleukin-6, a marker of inflammation, also increased during CPB.
    Conclusions: The present study demonstrates that CPB causes an increase in the concentration of plasma sCD40L. The corresponding decrease in platelet CD40L suggests that this prothrombotic and proinflammatory protein was derived primarily from platelets and may contribute to the thrombotic and inflammatory complications associated with CPB.
    MeSH term(s) Aged ; Biomarkers/blood ; Blood Platelets/chemistry ; CD40 Ligand/analysis ; CD40 Ligand/blood ; Cardiopulmonary Bypass/adverse effects ; Female ; Humans ; Inflammation/etiology ; Interleukin-6/blood ; Kinetics ; Male ; Platelet Activation ; Platelet Factor 4/analysis ; Thrombosis/etiology ; beta-Thromboglobulin/analysis
    Chemical Substances Biomarkers ; Interleukin-6 ; beta-Thromboglobulin ; CD40 Ligand (147205-72-9) ; Platelet Factor 4 (37270-94-3)
    Language English
    Publishing date 2002-06-18
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80099-5
    ISSN 1524-4539 ; 0009-7322 ; 0069-4193 ; 0065-8499
    ISSN (online) 1524-4539
    ISSN 0009-7322 ; 0069-4193 ; 0065-8499
    DOI 10.1161/01.cir.0000019068.32280.b3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui IV Zs.60: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top